← Diagnosis and Management Guides
COPD Stable Management
Key considerations: Lung cancer (shared risk factors), Heart failure masquerading as COPD, Alpha-1 antitrypsin deficiency in young patients
Cannot miss
- Lung cancer (shared risk factors)
- Heart failure masquerading as COPD
- Alpha-1 antitrypsin deficiency in young patients
Likely diagnoses
- COPD GOLD A-D
- Asthma-COPD overlap
- Bronchiectasis
- Heart failure with preserved EF
Red flags
- Age <40 with COPD (consider A1AT deficiency)
- Hemoptysis (malignancy)
- Rapid decline in FEV1
- BMI <21 (poor prognosis)
- Resting hypoxia (SpO2 <88%)
Workup
- history: Smoking history (pack-years), dyspnea severity (mMRC), exacerbation frequency, exercise tolerance; exam: Breath sounds, accessory muscle use, barrel chest, oxygen saturation, BMI; labs: Spirometry (FEV1/FVC <0.70 post-bronchodilator confirms diagnosis); A1AT level if age <45 or family history, CBC (polycythemia); imaging: Chest CT if malignancy concern, CXR baseline; bedside: 6-minute walk test, pulse oximetry, PHQ-9 (depression comorbidity), STOP-BANG (OSA)
Management
- immediate: Not applicable for stable management; general: Smoking cessation (most important intervention); GOLD A: SABA PRN, GOLD B: LAMA or LABA, GOLD C: LAMA, GOLD D: LAMA + LABA +/- ICS; Pulmonary rehab for all symptomatic patients; Annual influenza, pneumococcal, COVID vaccines; Supplemental O2 if resting SpO2 <=88% (reduces mortality)
Disposition
- admit: Not applicable for stable management; discharge: Outpatient management with regular follow-up; consults: Pulmonology for severe (GOLD C/D) or diagnostic uncertainty
Clinical pearls
- ICS monotherapy is NOT recommended in COPD — associated with increased pneumonia risk without sufficient benefit
- Use ICS only in combination with LABA and only in GOLD D or frequent exacerbators
- Smoking cessation is the only intervention proven to slow FEV1 decline
Source and review
- GOLD 2024 COPD Report. Last reviewed: 2024-11-01